Cost-utility of molecular adsorbent recirculating system treatment in acute liver failure

Table 4 The survival, cost, and HRQoL data of MARS-treated and control patients

	Subgroups according to outcome	3-yr survival			Cost (€)				HRQoL
		n	%	Mean (d)	n	Mean	Min	Max	n	Pre-treatment mean	Post-treatment mean
MARS group	All ALF patients	90	78		31	79 745	11 961	370 573	90	0.30	0.70
	Alive at 3 yr	70			24	78 724	11 961	370 573	70	0.34	0.89
	Dead	20		63	7	83 243	32 496	171 157	20	0.15	0.00
	Contraindication to Ltx	18	39
	Alive at 3 yr	7			4	52 492	30 325	112 585	7	0.38	0.85
	Dead	11		14	5	64 414	32 496	95 666	11	0.13	0.00
	No contraindication - no Ltx	46	85
	Alive at 3 yr	39			15	41 957	11 961	137 235	39	0.40	0.93
	Dead	7		110	1	89 471			7	0.09	0.00
	Transplanted	26	92
	Alive at 3 yr	24			5	210 012	96 984	370 573	24	0.22	0.84
	Dead	2		169	1	171 157			2	0.47	0.00
Control group	All ALF patients	17	41		16	105 820	16 862	262 481	17	0.27	0.36
	Contraindication to Ltx		0
	Dead	7		9	7	45 089	17 591	105 917	7	0.27	0.00
	No contraindication - no Ltx		100
	Alive at 3 yr	2			2	77 162	16 862	137 462	2	0.27	0.85
	Transplanted		63
	Alive at 3 yr	5			4	170 578	117 444	262 481	5	0.32	0.87
	Dead	3		28	3	180 285	129 120	250 772	3	0.19	0.00

HRQoL: Health-related quality of life; ALF: Acute liver failure.